golimumab   Click here for help

GtoPdb Ligand ID: 6776

Synonyms: CNTO-148 | CNTO148 | Simponi®
Approved drug Immunopharmacology Ligand
golimumab is an approved drug (FDA (2009), EMA (2009))
Compound class: Antibody
Comment: TNFα inhibitor.
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: golimumab

1. Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, Hsia EC, Han J, Wagner C, Xu Z et al.. (2008)
Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study.
Arthritis Rheum, 58 (4): 964-75. [PMID:18383539]
2. Shealy DJ, Cai A, Staquet K, Baker A, Lacy ER, Johns L, Vafa O, Gunn 3rd G, Tam S, Sague S et al.. (2010)
Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α.
MAbs, 2 (4): 428-39. [PMID:20519961]
3. Zhou H, Jang H, Fleischmann RM, Bouman-Thio E, Xu Z, Marini JC, Pendley C, Jiao Q, Shankar G, Marciniak SJ et al.. (2007)
Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.
J Clin Pharmacol, 47 (3): 383-96. [PMID:17322150]